What is the standard first-line therapy for mild-to-moderate Pneumocystis jirovecii pneumonia if no sulfa allergy?

Prepare for the Mycology Exam. Study with quizzes and multiple choice questions, each with hints and explanations. Master the subject!

Multiple Choice

What is the standard first-line therapy for mild-to-moderate Pneumocystis jirovecii pneumonia if no sulfa allergy?

The main idea here is that for Pneumocystis jirovecii pneumonia in patients who have no sulfa allergy, the best first-line treatment is high-dose TMP-SMX. This combination is highly effective against Pneumocystis, offers good lung penetration, and has a long track record of success in mild-to-moderate disease. Dosing is typically a high-dose regimen of trimethoprim-sulfamethoxazole given for about 14 to 21 days, with consideration of adjunctive corticosteroids if the patient is significantly hypoxemic. Dapsone with trimethoprim is reserved for people who cannot take TMP-SMX due to a sulfa allergy or intolerance, not for those without allergy. Other alternatives, such as clindamycin with primaquine, atovaquone, or pentamidine, are also considered when TMP-SMX cannot be used, but they are not the standard first-line in patients without sulfa allergy.

The main idea here is that for Pneumocystis jirovecii pneumonia in patients who have no sulfa allergy, the best first-line treatment is high-dose TMP-SMX. This combination is highly effective against Pneumocystis, offers good lung penetration, and has a long track record of success in mild-to-moderate disease. Dosing is typically a high-dose regimen of trimethoprim-sulfamethoxazole given for about 14 to 21 days, with consideration of adjunctive corticosteroids if the patient is significantly hypoxemic.

Dapsone with trimethoprim is reserved for people who cannot take TMP-SMX due to a sulfa allergy or intolerance, not for those without allergy. Other alternatives, such as clindamycin with primaquine, atovaquone, or pentamidine, are also considered when TMP-SMX cannot be used, but they are not the standard first-line in patients without sulfa allergy.

More practice questions